Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments of $314.0 million, with 97,954,172 shares of common stock outstanding. The ...

New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramideand ...

Cytokinetics (CYTK) announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...

HeartLung Technologies to debut its FDA designated "Breakthrough" AI technology (AutoChamberTM) at ACC 2025, offering lifesaving AI solutions for CVD prevention. Marlon Montes HeartLung Corporation +1 ...

Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...